PIQUR Therapeutics AG
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2011-08-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.piqur.com
Clinical Trials
18
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 9
- Registration Number
- NCT03127020
- Locations
- 🇩🇪
Medizinische Klinik und Poliklinik III, Munich, Bavaria, Germany
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- PIQUR Therapeutics AG
- Registration Number
- NCT03120000
- Locations
- 🇫🇷
Aix-Marseilles Université, Marseille, France
🇫🇷Service de Neurology CHRU de Nancy, Nancy, France
🇫🇷Hôpital Pitié-Sâlpétrier,, Paris, France
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 10
- Registration Number
- NCT02850744
- Locations
- 🇨🇭
University Hospital Zurich, Neurology, Zurich, Switzerland
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT02723877
- Locations
- 🇪🇸
Hospital Universitarsi Vall d'Hebron, Barcelona, Catalan, Spain
🇪🇸Insitut Català d´Oncologia, Barcelona, Spain
🇪🇸Fundación Instituto Valenciano de Oncología, Valencia, Spain
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT02669511
- Prev
- 1
- 2
- Next
News
Bimiralisib Gel Shows Promising Results in Phase 2 Trial for Actinic Keratosis
Torqur AG's interim Phase 2 results reveal 60% of patients experienced complete or partial clearance of actinic keratosis lesions, with the 4-week treatment group showing stronger response (70%) than the 2-week group (50%).